Takeda Pharmaceutical Company
Tracked across 7 events · 57 articles · First seen Feb 01, 2026 · Last active Apr 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Takeda Pharmaceutical Company terminated its collaboration agreement with Denali Therapeutics for DNL593 due to strategic considerations. This decision means Takeda will no longer co-develop or co-commercialize the investigational therapy.
Apr 03, 2026 · 7 articles
Business
Takeda Pharmaceutical Company is a partner with Protagonist Therapeutics for the co-development and potential co-commercialization of rusfertide. Protagonist Therapeutics expects to opt out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda Pharmaceuticals in Q2 2026.
Feb 25, 2026 · 7 articles
Regulatory
Takeda Pharmaceutical Company, a multinational innovator, may see increased patient numbers for its therapies in India due to the customs duty exemption on cancer drugs.
Feb 01, 2026 · 9 articles
Business
Takeda Pharmaceutical Company had senior leaders participate in the BIOSeedin Winter Innovation Partnering Summit, contributing to discussions on global strategies and innovation in the biopharmaceutical industry.
Feb 02, 2026 · 7 articles
Business
Takeda Pharmaceutical Company's leadership team met with the Chief Minister of India===Telangana to discuss propelling the life sciences ecosystem.
Feb 16, 2026 · 9 articles
+ 2 more events
View on Dashboard
NEWSDESK
Track Takeda Pharmaceutical Company live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard